Carisma Therapeutics Inc
CARM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.92K
Close$
$-0.29
58220% downside
Current Fair Value
58220% downsideOvervalued by 58220% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $20,923.00 |
|---|---|
| Enterprise Value | $-1,994,077.00 |
| Earnings per Share | $-1.46 |
| Beta | -9.6 |
| Outstanding Shares | 41,788,096 |
Return
| Return on Equity | -927.57% |
|---|---|
| Return on Assets | 122.70% |
| Return on Invested Capital | -8119.38% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -0.55 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.38 |
| Debt to Equity | -0.88 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.11
Consensus analyst estimateRevenue Estimate
$4.23 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.12
Consensus analyst estimateRevenue Estimate
$4.66 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 3.53% |
|---|---|
| Total Invested | $4▼ 99.99% |
| Investors Holding | 1▼ 2.00% |
About Carisma Therapeutics Inc
35 employees
CEO: Thomas Cannell
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage ...